Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Ingevity (NGVT) just posted second quarter 2026 results that show higher profitability compared with last year's loss, alongside lower sales and the completion of a multi year share repurchase program.
See our latest analysis for Ingevity.
At a share price of $73.11, Ingevity has gained 21.67% on a year-to-date share price basis, while the 1-year total shareholder return of 80.97% points to strong recent momentum despite some shorter-term pullbacks.
If this kind of earnings-driven move has your attention, it could be a good moment to see what else is setting up in the market with the 18 top founder-led companies
Ingevity now has improved profitability and a completed buyback behind it, along with a sharp share price run. The business looks stronger on paper. The key issue is whether the current valuation already reflects that strength.
The most followed valuation narrative for Ingevity puts fair value at $89 per share compared with the latest close of $73.11. That gap hinges on some ambitious profitability assumptions and a relatively low required return on future cash flows.
Analysts are assuming Ingevity's revenue will decrease by 1.4% annually over the next 3 years. Analysts assume that profit margins will increase from 13.2% below break even today to 31.0% in 3 years time.
Want to see how Ingevity gets from today's earnings base to that higher margin world? The narrative leans heavily on a sharp earnings ramp, richer margins and a future earnings multiple that sits below the wider chemicals sector. Curious which moving parts matter most to that $89 figure and how sensitive it is to those assumptions? The full narrative lays out the step by step path behind that call.
Result: Fair Value of $89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ingevity still faces meaningful risks, including pressure on Advanced Polymer Technologies margins and potential demand weakness in key industrial and automotive end markets that could challenge this upbeat narrative.
Find out about the key risks to this Ingevity narrative.
The analyst narrative leans on strong future earnings and a fair value of $89, yet Ingevity currently trades on a P/E of 100.9x. That is far above the fair ratio of 32.7x, the US Chemicals industry at 25.6x, and peer average of 23.4x. This rich multiple increases the valuation risk if growth falls short.
To see how this P/E gap fits into the wider picture of Ingevity and similar stocks, take a closer look at the See what the numbers say about this price — find out in our valuation breakdown.
If this mix of optimism and concern around Ingevity feels familiar, do not wait for someone else to decide what it means. Take a closer look at the balance of potential upside and downside by checking the 4 key rewards and 2 important warning signs
If Ingevity has sharpened your focus, do not stop here. Put a few more quality ideas on your radar now so you are not reacting later.
Target potential value opportunities early by scanning the 55 high quality undervalued stocks before other investors start paying attention.
Build a steadier income stream by reviewing the 9 dividend fortresses that combine higher yields with resilient fundamentals.
Reduce portfolio stress by focusing on the 81 resilient stocks with low risk scores that show stronger balance sheets and lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NGVT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]